{"entity":{"id":"cdkn2b","kind":"target","name":"CDKN2B","aka":["cyclin dependent kinase inhibitor 2B","Cyclin-dependent kinase 4 inhibitor B","P15","MTS2","INK4B","TP15","CDK4I","p15INK4b"],"tldr":"CDKN2B (Cyclin-dependent kinase 4 inhibitor B) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Renal cell carcinoma, Breast cancer and 5 more.","summary":"Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest.\n\nCIViC holds 8 clinical evidence items and 0 assertions across 5 variants, naming Palbociclib, Trametinib, Bevacizumab and Vemurafenib and others. Open Targets scores its association with cancer at 0.67 (direct and indirect evidence; datatypes genetic literature 0.30, affected pathway 0.76, literature 0.98, genetic association 0.70, somatic mutation 0.62).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:1788","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1788"},{"label":"UniProt P42772","url":"https://www.uniprot.org/uniprotkb/P42772/entry"},{"label":"NCBI Gene 1030","url":"https://www.ncbi.nlm.nih.gov/gene/1030"},{"label":"Ensembl ENSG00000147883","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147883"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets"],"cancers":["pancreatic","rcc","breast-cancer","skin-cancer","cholangiocarcinoma","ewing-sarcoma","apl","all-leukemia","gallbladder"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["sclc-signalling"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 9 therapies; CIViC holds 8 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate.","Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Ganglioglioma."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"CDKN2B","role":["drug-target","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:1788","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1788","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P42772","url":"https://www.uniprot.org/uniprotkb/P42772/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene CDKN2B","url":"https://civicdb.org/features/916","note":"8 evidence items, 0 assertions, 5 variants; diseases: Pancreatic Cancer, Cholangiocarcinoma, Ewing Sarcoma, Renal Cell Carcinoma, Acute Promyelocytic Leukaemia and 2 more (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000147883","url":"https://platform.opentargets.org/target/ENSG00000147883/associations","note":"association with cancer (MONDO_0004992) 0.67; per-cancer scores at or above 0.5: skin cancer 0.51, basal cell carcinoma 0.50, breast cancer 0.60 (GraphQL API, CC0)"}],"distribution":"many-types","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA CDKN2B: RNA tissue enhanced (esophagus 37 nTPM, intestine 29 nTPM); blood lineage lineage enriched (monocytes 9 nTPM); no normal tissue stained high; highest cancer staining liver cancer (3 of 11 high). Distribution: 7 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Biliary tract cancer (all types), Pancreatic ductal adenocarcinoma, Renal cell carcinoma, Breast cancer (all types), Skin cancer (all types), Sarcomas (soft tissue, bone, GIST), Leukaemia); Open Targets associates it with 4 specific cancer types at or above 0.5 (breast cancer, glioma, basal cell carcinoma, central nervous system cancer). (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas CDKN2B tissue","url":"https://www.proteinatlas.org/ENSG00000147883-CDKN2B/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000147883 associations","url":"https://platform.opentargets.org/target/ENSG00000147883/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:1788","ensembl":"ENSG00000147883","uniprot":"P42772","entrez":"1030","firstDescribed":1994,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Guan K.-L. et al, Genes Dev, 1994, \"Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/8001816/","biology":"Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest. Location: Cytoplasm (UniProt). Locus 9p21.3 (HGNC).","whereFound":["Pancreatic ductal adenocarcinoma: CIViC evidence names this disease","Renal cell carcinoma: CIViC evidence names this disease","Breast cancer: Open Targets association 0.60 with breast cancer (MONDO_0007254)","Skin cancer: Open Targets association 0.51 with skin cancer (MONDO_0002898)","Biliary tract cancer: CIViC evidence names this disease","Ewing sarcoma: CIViC evidence names this disease","Gallbladder cancer: deep deletion (with cdkn2a) about 14%"],"targetClass":"other","prevalence":[{"cancerId":"gallbladder","pct":14,"measure":"Deep deletion (with CDKN2A)","source":"https://www.cbioportal.org/study/summary?id=gbc_mskcc_2022","note":"Deep deletion in 34 of 244 samples, 13.9%, in cBioPortal gbc_mskcc_2022 and 12 of 103, 11.7%, in gbc_msk_2018; co-deleted with CDKN2A on 9p21."}]},"route":"/targets/cdkn2b/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"apl","kind":"cancer","name":"Acute promyelocytic leukaemia","route":"/cancers/apl/"},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"ewing-sarcoma","kind":"cancer","name":"Ewing sarcoma","route":"/cancers/ewing-sarcoma/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"}],"pathway":[{"id":"sclc-signalling","kind":"pathway","name":"Small cell lung cancer (KEGG map)","route":"/pathways/sclc-signalling/"}]}}